RxDoctor Payments Data

Sidney Schechet, MD

Retina Specialist · Baltimore, MDNPI 1659714707

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Alimera Sciences, Inc. at 44.1% of the total. Reporting peaked in 2020 at $8,224 and has fallen 98.2% since, to $150 in 2025.

$22,661in general payments, 2019–2025

Across 105 payments — averaging $215.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alimera Sciences, Inc.$10K
  • Biogen$6K
  • AbbVie$4K
  • Regeneron$1K
  • Genentech USA, Inc.$533
  • Regeneron Healthcare Solutions, Inc.$399
  • plus $1K from 10 others
$810in research payments, 2019–2025

Across 19 payments — averaging $42.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Notal Vision, Inc.$810

What the payments were for

  • Consulting fees$6,31128%
  • Speaking & faculty fees$12,75856%
  • Travel & lodging$1,1295%
  • Food & beverage$2,37010%
  • Education$940%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,661 in reported general payments places this provider in the 85th percentile of 47 retina specialist providers in Maryland.

See all retina specialist providers in Maryland

Medicare billing

Part B allowed, 2024
$4,274,515
Medicare patients
1,121
Services billed
76,965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bromfenac Sodium180$32,017
ProlensaBromfenac Sodium74$29,577
IlevroNepafenac17$6,218
Prednisolone Acetate113$5,704
Ketorolac Tromethamine211$4,275
Lotemax SmLoteprednol Etabonate11$3,408
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat43$616
Dorzolamide Hcl39$506
MoxifloxacinMoxifloxacin Hcl19$305
Diclofenac Sodium26$274
Latanoprost15$140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisIlevro$220$6,21817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 47 retina specialist providers in Maryland.

Other retina specialist in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →